← Leaderboards
Jian Li
Monash University
$20,228,860
Attributed
$31,425,794
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,425,794 · 10
By mechanism
R01$31,077,814 · 9
R21$347,980 · 1
Top collaborators
- Qi Zhou11 shared
- Keith S Kaye5 shared
- Brian Tsuji5 shared
- Tony Velkov5 shared
- Yuanpu Peter Di2 shared
- Jason Michael Pogue1 shared
Others in their field
Top investigators on “Polymyxins”
- Daniel E Kahne · Harvard University$7,224,125
- Eduardo A. Groisman · Washington University$4,854,183
- Brian Tsuji · State University Of New York At Buffalo$4,184,203
- Terry Roemer · Prokaryotics, Inc.$3,976,991
- Christian C Melander · California Institute Of Technology$3,706,594
- Michael Stephen Trent · University Of Georgia$3,685,392
Research focus
PolymyxinsAntibioticsPolymyxin ResistanceDrug KineticsPathogenToxic EffectMulti-Drug ResistanceInfectionSuperbugAcinetobacter BaumanniiPharmaceutical PreparationsNephrotoxicityColistinPharmacodynamicsResistancePseudomonas AeruginosaPolymyxin BCombatPharmacologyClinicReportingBaseCommunicable DiseasesSocieties
Grant awards (41)
Aerosol delivery of combinational therapeutics targeting deadly lung infections$594,930
R01 · FY2025 · HL
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms$867,033
R01 · FY2024 · AI
Aerosol delivery of combinational therapeutics targeting deadly lung infections$614,933
R01 · FY2024 · HL
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms$880,743
R01 · FY2023 · AI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$646,188
R01 · FY2023 · AI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$639,543
R01 · FY2022 · AI
Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach$137,249
R21 · FY2022 · AI · contact PI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$840,469
R01 · FY2021 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$646,174
R01 · FY2021 · AI
Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach$210,731
R21 · FY2021 · AI · contact PI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$840,469
R01 · FY2020 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$642,515
R01 · FY2020 · AI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$573,080
R01 · FY2020 · AI
Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs$1,019,318
R01 · FY2019 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$794,600
R01 · FY2019 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$673,485
R01 · FY2019 · AI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$565,399
R01 · FY2019 · AI
Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs$1,043,666
R01 · FY2018 · AI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$934,289
R01 · FY2018 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations$819,605
R01 · FY2018 · AI · contact PI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$793,759
R01 · FY2018 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$614,336
R01 · FY2018 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$1,059,804
R01 · FY2017 · AI · contact PI
Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs$1,046,856
R01 · FY2017 · AI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$857,287
R01 · FY2017 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations$855,749
R01 · FY2017 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$650,259
R01 · FY2017 · AI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides$996,973
R01 · FY2016 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$928,854
R01 · FY2016 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations$874,635
R01 · FY2016 · AI · contact PI
Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs$720,000
R01 · FY2016 · AI
Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat Superbugs$253,967
R01 · FY2016 · AI
Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat Superbugs$924,298
R01 · FY2015 · AI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$902,595
R01 · FY2015 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations$893,305
R01 · FY2015 · AI · contact PI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides$838,537
R01 · FY2015 · AI · contact PI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations$905,775
R01 · FY2014 · AI · contact PI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides$829,212
R01 · FY2014 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$825,019
R01 · FY2014 · AI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides$755,045
R01 · FY2013 · AI · contact PI
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides$915,110
R01 · FY2012 · AI · contact PI